A DNA sequence encoding the human LIPF (Met1-Lys398) was expressed with a C-terminal polyhistidine tag.
The secreted recombinant human LIPF consists of 389 amino acids and predicts a molecular mass of 44.6 KDa. The apparent molecular mass of the protein is approximately 45 KDa in SDS-PAGE under reducing conditions.
The protein Gastric triacylglycerol lipase (LIPF) is the target for the small-molecule antagonist Orlistat (brand names Alli and Xenical), which is used to treat obesity by preventing the absorption of fats from the diet. LIPF is an enzyme that hydrolyzes triglycerides into absorbable free fatty acids in the intestine, here shown in the glandular cells in stomach by immunohistochemical staining with the antibody.
> 95 % as determined by SDS-PAGE
Lyophilized from sterile PBS, pH 7.4.
This protein is used to treat obesity by preventing the absorption of fats from the diet.
Examples of Clinical Use:
Treating obesity by preventing the absorption of fats from the diet.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.